Celularity Inc
NASDAQ:CELU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Celularity Inc
NASDAQ:CELU
|
US |
Celularity Inc
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
